Leerink Partnrs Has Bearish Estimate for JAZZ Q3 Earnings

Key Points

• Leerink Partners has reduced its Q3 2025 earnings per share estimate for Jazz Pharmaceuticals from $4.85 to $4.69, while maintaining a full-year earnings consensus of $16.96 per share.
• Despite the bearish estimate, the stock received a buy rating from multiple analysts, with price targets as high as $205.00, indicating continued confidence in its future performance.
• Jazz Pharmaceuticals reported a significant loss of ($8.25) EPS for the last quarter, missing expectations and reflecting a challenging financial landscape for the company.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) - Equities researchers at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for Jazz Pharmaceuticals in a note issued to investors on Monday, October 6th. Leerink Partnrs analyst M. Goodman now anticipates that the specialty pharmaceutical company will earn $4.69 per share for the quarter, down from their previous forecast of $4.85. The consensus estimate for Jazz Pharmaceuticals' current full-year earnings is $16.96 per share. Leerink Partnrs also issued estimates for Jazz Pharmaceuticals' Q4 2025 earnings at $5.22 EPS and FY2026 earnings at $19.47 EPS.

Several other equities analysts also recently weighed in on the company. Weiss Ratings reiterated a "sell (d)" rating on shares of Jazz Pharmaceuticals in a research report on Wednesday. Truist Financial increased their target price on Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a "buy" rating in a research report on Thursday, August 28th. Morgan Stanley raised their price objective on Jazz Pharmaceuticals from $163.00 to $167.00 and gave the stock an "overweight" rating in a report on Wednesday, September 24th. Royal Bank Of Canada raised their price objective on Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an "outperform" rating in a report on Thursday, August 28th. Finally, The Goldman Sachs Group increased their target price on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a "buy" rating in a research note on Friday, August 29th. Fourteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $178.93.

Jazz Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ:JAZZ opened at $137.78 on Thursday. The stock's fifty day simple moving average is $125.01 and its 200-day simple moving average is $115.78. Jazz Pharmaceuticals has a 52-week low of $95.49 and a 52-week high of $148.06. The company has a market capitalization of $8.36 billion, a P/E ratio of -20.47, a P/E/G ratio of 8.43 and a beta of 0.28. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion during the quarter, compared to analysts' expectations of $1.05 billion. During the same quarter in the prior year, the company earned $5.30 earnings per share. The firm's revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS.

Institutional Trading of Jazz Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. Teacher Retirement System of Texas lifted its holdings in shares of Jazz Pharmaceuticals by 0.6% in the 2nd quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company's stock worth $1,651,000 after purchasing an additional 90 shares during the last quarter. Kendall Capital Management raised its stake in Jazz Pharmaceuticals by 1.2% during the 1st quarter. Kendall Capital Management now owns 7,964 shares of the specialty pharmaceutical company's stock valued at $989,000 after acquiring an additional 95 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in Jazz Pharmaceuticals by 0.6% during the 1st quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company's stock valued at $2,098,000 after acquiring an additional 100 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych raised its stake in Jazz Pharmaceuticals by 8.7% during the 2nd quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,250 shares of the specialty pharmaceutical company's stock valued at $133,000 after acquiring an additional 100 shares in the last quarter. Finally, Sound View Wealth Advisors Group LLC raised its stake in Jazz Pharmaceuticals by 1.3% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company's stock valued at $1,046,000 after acquiring an additional 110 shares in the last quarter. Institutional investors own 89.14% of the company's stock.

Insider Activity

In related news, Director Bruce C. Cozadd sold 3,500 shares of the firm's stock in a transaction that occurred on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total value of $490,000.00. Following the sale, the director owned 408,826 shares of the company's stock, valued at approximately $57,235,640. This trade represents a 0.85% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last 90 days, insiders sold 11,500 shares of company stock valued at $1,525,280. Company insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.